A Company Focused on Improving Care for People with MASH
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in an ongoing Phase 3 outcomes trial for the treatment of MASH with compensated cirrhosis (consistent with stage F4c).
Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Minimum 15 minutes delayed. Source: LSEG
